Details

Autor(en) / Beteiligte

• Abrisqueta, Pau
• Villamor, Neus
• Terol, María José
• González-Barca, Eva
• González, Marcos
• Ferrà, Christelle
• Abella, Eugenia
• Delgado, Julio
• García-Marco, Jose A.
• González, Yolanda
• Carbonell, Felix
• Ferrer, Secundino
• Monzó, Encarna
• Jarque, Isidro
• Muntañola, Ana
• Constants, Mireia
• Escoda, Lourdes
• Calvo, Xavier
• Bobillo, Sabela
• Montoro, José Bruno
• Montserrat, Emili
• Bosch, Francesc

Titel

Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia

Ist Teil von

• Blood, 2013-12, Vol.122 (24), p.3951-3959

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2013

Quelle

MEDLINE

Beschreibungen/Notizen

• The effectiveness of rituximab maintenance therapy in the treatment of chronic lymphocytic leukemia has been investigated in a phase 2 clinical trial that included an initial treatment with rituximab 500 mg/m2 on day 1 (375 mg/m2 the first cycle), fludarabine 25 mg/m2 on days 1 to 3, cyclophosphamide 200 mg/m2 on days 1 to 3, and mitoxantrone 6 mg/m2 on day 1 (R-FCM), for 6 cycles, followed by a maintenance phase with rituximab 375 mg/m2 every 3 months for 2 years. Sixty-seven patients having achieved complete response (CR) or partial response (PR) with R-FCM were given maintenance therapy. At the end of maintenance, 40.6% of patients were in CR with negative minimal residual disease (MRD), 40.6% were in CR MRD-positive, 4.8% remained in PR, and 14% were considered failures. Six of 29 patients (21%) who were in CR MRD-positive or in PR after R-FCM improved their response upon rituximab maintenance. The 4-year progression-free survival (PFS) and overall survival rates were 74.8% and 93.7%, respectively. MRD status after R-FCM induction was the strongest predictor of PFS. Maintenance with rituximab after R-FCM improved the quality of the response, particularly in patients MRD-positive after initial treatment, and obtained a prolonged PFS. This trial was registered at www.clinicaltrialsregister.eu as identifier #2005-001569-33. •Maintenance rituximab attained a prolonged PFS and improved the quality of response in patients with detectable disease after R-FCM.